REGISTERED NUMBER: |
Unaudited Financial Statements for the Year Ended 30 September 2023 |
for |
Nature Medical Limited |
REGISTERED NUMBER: |
Unaudited Financial Statements for the Year Ended 30 September 2023 |
for |
Nature Medical Limited |
Nature Medical Limited (Registered number: 08691048) |
Contents of the Financial Statements |
for the Year Ended 30 September 2023 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 4 |
Report of the Accountants | 9 |
Nature Medical Limited |
Company Information |
for the Year Ended 30 September 2023 |
DIRECTOR: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Chartered Accountants |
434 Finchley Road |
London |
NW2 2HY |
Nature Medical Limited (Registered number: 08691048) |
Balance Sheet |
30 September 2023 |
30.9.23 | 30.9.22 |
Notes | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
Investments | 5 |
Investment property | 6 |
CURRENT ASSETS |
Stocks | 7 |
Debtors | 8 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 9 | ( |
) | ( |
) |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
PROVISIONS FOR LIABILITIES | 10 | ( |
) | ( |
) |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 11 |
Revaluation reserve | 12 |
Capital redemption reserve | 12 |
Retained earnings | 12 |
SHAREHOLDERS' FUNDS |
The director acknowledges his responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
Nature Medical Limited (Registered number: 08691048) |
Balance Sheet - continued |
30 September 2023 |
The financial statements were approved by the director and authorised for issue on |
Nature Medical Limited (Registered number: 08691048) |
Notes to the Financial Statements |
for the Year Ended 30 September 2023 |
1. | STATUTORY INFORMATION |
Nature Medical Limited is a |
The presentation currency of the financial statements is the Pound Sterling (£). |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
Tangible fixed assets |
Tangible fixed assets: 25% on reducing balance method |
Investment property |
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss. |
Stocks |
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
Research and development |
Expenditure on research and development is written off in the year in which it is incurred. |
Nature Medical Limited (Registered number: 08691048) |
Notes to the Financial Statements - continued |
for the Year Ended 30 September 2023 |
2. | ACCOUNTING POLICIES - continued |
Pension costs and other post-retirement benefits |
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
4. | TANGIBLE FIXED ASSETS |
Fixtures |
and | Computer |
fittings | equipment | Totals |
£ | £ | £ |
COST |
At 1 October 2022 |
and 30 September 2023 |
DEPRECIATION |
At 1 October 2022 |
Charge for year |
At 30 September 2023 |
NET BOOK VALUE |
At 30 September 2023 |
At 30 September 2022 |
5. | FIXED ASSET INVESTMENTS |
30.9.23 | 30.9.22 |
£ | £ |
Other investments not loans |
Additional information is as follows: |
Listed |
investments |
£ |
COST OR VALUATION |
At 1 October 2022 |
Share of profit/(loss) | (131,555 | ) |
Revaluations | ( |
) |
At 30 September 2023 |
NET BOOK VALUE |
At 30 September 2023 |
At 30 September 2022 |
Nature Medical Limited (Registered number: 08691048) |
Notes to the Financial Statements - continued |
for the Year Ended 30 September 2023 |
5. | FIXED ASSET INVESTMENTS - continued |
Cost or valuation at 30 September 2023 is represented by: |
Listed |
investments |
£ |
Valuation in 2021 | 240,620 |
Investments (neither listed nor unlisted) were as follows: |
30.9.23 | 30.9.22 |
£ | £ |
Paintings - cost b/f | 25,730 | 25,730 |
Paintings disposal | (13,200 | ) | - |
Share of loss/profit | (12,530 | ) | - |
- | 25,730 |
The listed shares are carried at the value from 2022. The directors have determined the value of investments to be same as 2022. |
Other investments relate to Paintings/artwork. These are stated at cost; as their current value is likely to be at least equal to their cost, due to their recent acquisition. |
6. | INVESTMENT PROPERTY |
Total |
£ |
COST OR VALUATION |
At 1 October 2022 |
and 30 September 2023 |
NET BOOK VALUE |
At 30 September 2023 |
At 30 September 2022 |
Directors have determined the value of the investment properties to be same as 2021. |
7. | STOCKS |
30.9.23 | 30.9.22 |
£ | £ |
Closing stock |
8. | DEBTORS |
30.9.23 | 30.9.22 |
£ | £ |
Amounts falling due within one year: |
Trade debtors |
Other debtors - Loan |
Paypal | 15,062 | 11,531 |
S455 tax paid | 448,525 | 268,061 |
Nature Medical Limited (Registered number: 08691048) |
Notes to the Financial Statements - continued |
for the Year Ended 30 September 2023 |
8. | DEBTORS - continued |
30.9.23 | 30.9.22 |
£ | £ |
Amounts falling due after more than one year: |
Other debtors - Loan > 1 year |
DR R J Thomas | 526,484 | - |
Aggregate amounts |
9. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
30.9.23 | 30.9.22 |
£ | £ |
Trade creditors | ( |
) |
Other creditors | 437 | 6,258 |
Tax |
Social security and other taxes |
VAT | 50,278 | 62,991 |
Directors' current accounts | - | 359 |
Accrued expenses |
10. | PROVISIONS FOR LIABILITIES |
30.9.23 | 30.9.22 |
£ | £ |
Deferred tax |
Accelerated capital allowances |
Other timing differences | (152 | ) | (155 | ) |
505 | 502 |
Deferred |
tax |
£ |
Balance at 1 October 2022 |
Charge to Income Statement during year |
Balance at 30 September 2023 |
11. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal | 30.9.23 | 30.9.22 |
value: | £ | £ |
Ordinary | 1 | 93 | 93 |
Nature Medical Limited (Registered number: 08691048) |
Notes to the Financial Statements - continued |
for the Year Ended 30 September 2023 |
12. | RESERVES |
Capital |
Retained | Revaluation | redemption |
earnings | reserve | reserve | Totals |
£ | £ | £ | £ |
At 1 October 2022 | 2,409,912 |
Profit for the year |
Dividends | ( |
) | ( |
) |
Transfer to/from reserves | - | (8,435 | ) | - | (8,435 | ) |
At 30 September 2023 | 2,321,764 |
Nature Medical Limited |
Report of the Accountants to the Director of |
Nature Medical Limited |
The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies. |
As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 30 September 2023 set out on pages two to four and you consider that the company is exempt from an audit. |
In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us. |
Chartered Accountants |
434 Finchley Road |
London |
NW2 2HY |